Improving the Value of Costly Genetic Reference Laboratory Testing With Active Utilization Management

Jane A. Dickerson, PhD; Bonnie Cole, MD; Jessie H. Conta, MS; Monica Wellner, BS; Stephanie E. Wallace, MD; Rhona M. Jack, PhD; Joe Rutledge, MD; Michael L. Astion, MD, PhD

• Context.—Tests that are performed outside of the ordering institution, send-out tests, represent an area of risk to patients because of complexity associated with sending tests out. Risks related to send-out tests include increased number of handoffs, ordering the wrong or unnecessary test, specimen delays, data entry errors, preventable delays in reporting and acknowledging results, and excess financial liability. Many of the most expensive and most misunderstood tests are send-out genetic tests.

• Objective.—To design and develop an active utilization management program to reduce the risk to patients and improve value of genetic send-out tests.

• Design.—Send-out test requests that met defined criteria were reviewed by a rotating team of doctoral-level consultants and a genetic counselor in a pediatric tertiary care center.

• Results.—Two hundred fifty-one cases were reviewed during an 8-month period. After review, nearly one-quarter of genetic test requests were modified in the downward direction, saving a total of 2% of the entire send-out bill and 19% of the test requests under management. Ultimately, these savings were passed on to patients.

• Conclusions.—Implementing an active utilization strategy for expensive send-out tests can be achieved with minimal technical resources and results in improved value of testing to patients.


Liu et al9 reported a successful utilization intervention in the Calgary medical system that reduced the volume of send-out tests by 50%, simply by requiring written clinical justification for any test costing more than $20 within 2 weeks or the test would be canceled. Although effective, this technique would likely be difficult to implement in many US hospital systems. Instead, send-out test utilization strategies that have been successfully implemented in the United States include the creation of formal utilization committees, pop-up reminders in computerized physician order entry, use of laboratory medicine or pathology residents to review test orders, and implementation of send-out formularies.5–7

Currently, some of the most misunderstood, controversial, and expensive tests are molecular genetic tests. We began by focusing primarily on this group of referred tests. Although genetic tests hold great promise for improving individual patient care, spending on genetic testing in the United States is trending upward at a rate of about 20% per year and the trend is expected to continue.8 New tests are being developed at a rapid rate. However, the utility of many genetic tests has yet to be proven. The technology and prices evolve rapidly, making it difficult for busy clinicians to stay current with the costs and benefits of any particular genetic test.9,10 Specialists who are not geneticists often find themselves outside their comfort zone when ordering genetic tests, especially when a genetic disease is low on their differential diagnosis. A report by ARUP (Salt Lake City, Utah) showed one-third of genetic tests were ordered in error, and using a genetic counselor in the laboratory decreased errors in genetic test ordering.11
There are other problems associated with genetic testing. Many genetic tests are routinely bundled as mutational analyses of large gene panels, even though only a small subset of these genes account for most instances of a given genetic disease. Bundling promotes overtesting and wasteful expense that can often be reduced with sequential testing strategies. In addition, obscure test names are difficult for clinicians and laboratory personnel to decipher and can lead to errors in test ordering. To add to this complexity, turnaround time for many genetic tests is on the order of weeks to months. Long turnaround times increase the risk that test results are not retrieved, potentially leading to a delayed diagnosis or even misdiagnosis. All of these factors contribute to poor utilization of these expensive tests.

In this paper, we report strategies that we developed to increase the value of testing for our patients. It is our hope that some of these strategies can be used by other institutions to improve test utilization for larger groups of patients.

METHODS

Hospital Setting

Seattle Children’s Hospital (Seattle, Washington) is a 250-bed care center and a teaching hospital associated with the University of Washington, School of Medicine. The Department of Laboratories performs more than 600 different clinical laboratory tests and processes more than 1 million requisitions per year. Tests not performed in-house account for an additional 40,000 tests per year, and these are sent to more than 100 reference laboratories across the country. Three full-time staff members are responsible for receiving, ordering, packaging, and processing results for all tests that are sent to other reference laboratories. The majority of these tests (82%) are sent to 2 major reference laboratories that have electronic interfaces for ordering and resulting tests.

Design

We designed a rotation of 3 doctoral-level faculty (2 clinical pathologists and 1 clinical chemist) and 1 genetic counselor to review send-out requests that met predefined criteria shown in Table 1. They include tests costing the laboratory more than $1000, multiple genetic tests on the same requisition, requests to nonpreferred laboratories, requests to international laboratories, and tests that are normally performed in-house. The $1000 cutoff was arbitrarily chosen because the volume of tests costing more than $1000 was deemed to be manageable given the current resources dedicated to this study. Tests that met the criteria were labeled “UM,” short for “utilization management,” in the laboratory information system so that they were automatically flagged by the send-out processing team to review. The send-out team forwarded the request to the on-call consultant for adjudication. The on-call consultant used a time-out process that included the following: confirming that the correct test was ordered, checking that there was documentation of medical necessity, encouraging of insurance preauthorization, and suggesting sequential testing strategies when appropriate. This process was achieved either by chart review or by direct discussion with the ordering provider. A template was created to e-mail the provider or guide verbal conversations. A brief chart review (less than 5 minutes) was performed with each case to determine if the intended test had been ordered, if the provider had documented medical necessity in the record, and if preauthorization had been attempted or was required. For example, many gene names are very similar and may differ by only one letter, so we checked for typographic errors. If a provider orders SCN1A gene testing, we asked whether the provider intended to order SCNTA testing. If it was not clear that these steps were complete, a conversation was initiated with the provider using the standard communication template. Because we recognized the complexity of care in our pediatric population, we did not attempt to strictly determine medical necessity by asking if the testing would directly change patient management, and instead we asked only that the provider’s rationale and discussion with the family be documented in the record. Ultimately, it was the ordering provider’s decision to proceed, modify, or cancel the test.

Each case was documented in a Microsoft Access (Bellevue, Washington) database to ensure consistency in case adjudication. Time to review a case ranged from 5 minutes to 2 hours of consultant time, with an average time of 15 minutes. The most time-consuming step was identifying and reaching the appropriate care provider(s) to have the discussion. In more complex cases, conversations might also occur with the performing laboratory to get more information about a test, or arrange for sequential testing. All cases were adjudicated within a week of the order date. This was considered acceptable for most molecular tests, for which the average turnaround time is approximately 4 to 6 weeks. Any specimens with stability issues (eg, Fanconi anemia breakage studies) were handled within 1 day. We handled stat and clinically urgent requests on an individual basis (eg, neonatal intensive care unit requests for multiple gene tests for surfactant deficiencies were sent simultaneously instead of sequentially). This study was approved by the Seattle Children’s Hospital Institutional Review Board.

RESULTS

In all, 251 cases met the defined criteria during an 8-month period and were reviewed by the utilization management committee. This committee met weekly to discuss cases and come to a consensus on how to manage certain types of cases in a uniform manner. Policies and procedures were created to help guide these efforts. Table 2 summarizes the cases. Seventy-six percent of the cases were approved without modification. A combined total of 24% of the genetic test requests were modified in the downward direction, either through sequential testing (11%) or cancelation (13%). This corresponds to a savings of $118,952 (19% of the total cost of requests, $610,456) for the laboratory, resulting in an average savings of $463 per test request under management (Table 3). The exact savings

<table>
<thead>
<tr>
<th>Table 1. Criteria for Tests Under Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tests costing the laboratory &gt;$1000</td>
</tr>
<tr>
<td>Multiple genetic tests on same requisition</td>
</tr>
<tr>
<td>Requests to send to nonpreferred laboratory</td>
</tr>
<tr>
<td>Requests to send to international laboratories</td>
</tr>
<tr>
<td>Requests to send tests that are performed in-house</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Modification Rate of Cases Reviewed Under Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>All (n = 251)</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Approved, % (No.)</td>
</tr>
<tr>
<td>Sequential, % (No.)</td>
</tr>
<tr>
<td>Cancelled, % (No.)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Financial Effect of Utilization Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amount, $</td>
</tr>
<tr>
<td>Total cost of requests</td>
</tr>
<tr>
<td>Cost saved*</td>
</tr>
<tr>
<td>Total spent</td>
</tr>
<tr>
<td>Average savings/test request</td>
</tr>
</tbody>
</table>

* Cost saved is 19% of total cost of requests.

Improving Value of Reference Laboratory Testing—Dickerson et al

Arch Pathol Lab Med—Vol 138, January 2014
to patients are difficult to calculate because of the variety of
payers involved. We estimate that the impact to patients is
significant because of the high cost of each test and markup
on send-out tests. We reviewed a number of individual
cases to evaluate the true cost to patients, which is
represented in the composite case (Figure 1).
We hypothesized that nongeneticists would use the
majority of our utilization management service. Figure 2
shows the breakdown of genetic test orders by specialty.
More than half (55%) were ordered by nongenetic
providers. Not surprisingly, the nongenetic providers also
required more of the consultant’s time. Although 46% of all
cases were adjudicated with a simple chart review, the
majority (75%) of the test requests from genetic providers
were handled in this manner. In contrast, 66% of the
requests from nongenetic providers were handled with an e-
mail or phone discussion with the ordering provider.

COMMENT
Active utilization management benefits patients by
decreasing the total cost of testing, and ultimately increasing
the value of the test. This intervention included encouraging
providers to obtain insurance preauthorization before
ordering the test. Preauthorization increases the likelihood
that a test will be covered by private insurance, and also
provides incentive for the provider to document rationale
and clinical necessity in the electronic medical record.
Ultimately, this helps to reduce unnecessary testing, or
“curiosity” testing practices. To support this process, we
implemented a DNA banking and sample hold policy to
limit redraws while waiting for preauthorization. Nearly a
quarter of the tests under management were modified or
canceled; these patients likely had the most benefit.
Reduction or elimination of the laboratory bill could be
viewed as an immediate financial benefit to the family.
Thoughtful test ordering also decreases the risk of false
positives and false negatives, especially in low-prevalence
populations. Ordering a test when the chance of false
positives is high can lead to a diagnostic testing cascade,
incuring unnecessary costs and anxiety for the family.
Conversely, ordering the wrong test and getting a negative
result can be falsely reassuring.

An unintended benefit of our intervention was discovered
in our case documentation using an Access database. We
tracked results for sequential test requests in order to
facilitate efficient sequential testing. This allowed us to
communicate results to providers and to decrease the risk of
unacknowledged results.

Although the ultimate goal of this intervention was to
increase value to patients, we also saw a benefit to our
institution. The policy at Seattle Children’s is to pay for all
reference laboratory testing by institutional billing and then
seek reimbursement from the patient’s insurance company
or use donated uncompensated care funds for qualifying
families. Some of the reasons for this policy include
contractual obligations with insurance payers and billing
requirements of reference laboratories. This practice to not
pass on patient billing information to reference laboratories
is common among hospitals because of the difficulty in
separating ambulatory patients from inpatients, which
would be necessary to achieve billing compliance. The end
result is that Seattle Children’s, like many hospitals, pays the
total price billed by the reference laboratory for reference
testing on every patient, independent of insurance coverage.
The cases involved in this intervention represented only
0.6% of our annual send-out test volume, but dispropor-
tionately represented 10% of the total send-out bill. To date,
we have saved 2% of the entire send-out bill. Any savings
allows the laboratory to redirect resources to in-house
testing and specimen processing.

Figure 1. Composite case of test request modification after review by utilization man-
agement program.

Figure 2. Genetic test requests by provider specialty. Abbreviation: Heme-Onc, hemat-
ology oncology service.
Overall, the implementation of the utilization intervention was a relatively simple process that can be implemented in a variety of hospital settings. It is low-tech, requiring limited laboratory information system involvement by adding “UM” to defined test names. Dedicated resources are required, but can be managed with just a few faculty and staff, which could include a mixture of pathologists, clinical chemists, clinical microbiologists, genetic counselors, and residents or fellows. The 3 doctoral-level consultants each dedicated a maximum of 0.1 full-time equivalents to the utilization management project and the laboratory genetic counselor devoted 0.4 full-time equivalents, which is a total of 0.7 full-time equivalents. This time includes development of the process (ie, training), development of the communication tools and database, and data input and analysis. On average, a doctoral-level consultant costs our hospital $192 000/y in salary and benefits, and a genetic counselor costs $98 000/y. Weighted appropriately, this accounts for a total of $96 800/y devoted to utilization management. Our study took place in an 8-month period, which corresponds to approximately $64 533. With the savings of $118 952 in testing not sent, we can justify the time spent to achieve this, especially with the understanding that this initial investment built the foundation to expand the intervention in the future without proportionally increasing the costs.

We also found that our providers were generally appreciative and happy with the service. Because we focused the conversations on the patient’s best interest, and stressed that the final decision was the provider’s, we did not encounter significant negative feedback. Many providers were, in fact, relieved to learn of review, especially when we encountered significant negative feedback. Many providers that the final decision was the provider’s, we did not appreciate and happy with the service. Because we focused on the patient’s best interest, and stressed that the final decision was the provider’s, we did not encounter significant negative feedback. Many providers were, in fact, relieved to learn of review, especially when we encountered significant negative feedback. Many providers

Prepared Now for the CAP ‘14 Abstract Program

Don’t Wait! Plan now to submit abstracts and case studies for the College of American Pathologists (CAP) 2014 meeting, which will be held September 7th through the 10th in Chicago, Ill. Submissions for the CAP ‘14 Abstract Program will be accepted from:

Monday, January 13, 2014 through Friday, March 14, 2014

Accepted submissions will appear online on the Archives of Pathology & Laboratory Medicine Web site. Visit the CAP ‘14 website at http://www.cap.org/cap14 for additional abstract program information as it becomes available.

References